DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Questions
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://link.springer.com/article/10.1007/s11864-014-0274-8, but it redirected us to https://link.springer.com/article/10.1007/s11864-014-0274-8. The analysis below is for the second page.

Title[redir]:
Ibrutinib in B-cell Lymphomas | Current Treatment Options in Oncology
Description:
The standard frontline therapy for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) includes the use of chemoimmunotherapy and/or radiation therapy. When patients with these diseases relapse or are refractory to therapy, their diseases are considered incurable outside of the setting of an autologous or allogeneic stem cell transplant, which many patients are not candidates for due to age or comorbidities. The oral Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, targets the B-cell receptor (BCR) signaling pathway that is critical in the survival of these malignancies. It has shown promising activity in certain subtypes of DLBCL, in relapsed or refractory FL, and in relapsed or refractory MCL for which it has recently received FDA approval and should be considered for use in patients in first relapse. Ibrutinib is an oral therapy taken daily that has been well tolerated by patients. Given the high response rates, tolerability, and acceptable toxicities of ibrutinib therapy, it is now being evaluated in combination therapy both in relapsed B-cell malignancies and frontline studies in DLBCL and MCL. Several other promising agents targeting different kinases in the BCR signaling pathway also are currently under investigation.

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don't see any clear sign of profit-making.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Doi.org might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

lymphoma, article, google, scholar, pubmed, patients, study, cas, phase, rituximab, bcell, oncol, abstract, cell, clin, ibrutinib, blood, relapsed, mantle, mcl, therapy, follicular, refractory, trial, treatment, relapsedrefractory, lenalidomide, kinase, nonhodgkins, results, multicenter, dlbcl, tyrosine, inhibitor, diffuse, large, brutons, chop, chemotherapy, randomized, mantlecell, analysis, lymphomas, autologous, malignancies, combination, group, aggressive, privacy, cookies,

Topics {✒️}

bcl-2-specific bh3-mimetic abt-199 relapsed/refractory b-cell malignancies hypercvad mtx/ara-cand rituximab relapsed/refractory b-cell lymphoma large b-cell lymphoma long-term progression-free survival b-cell receptor cd20 positive b-cell relapsed b-cell malignancies limited-stage diffuse aggressive b-cell lymphomas lymphoma r-chop versus r-fc month download article/chapter refractory mantle-cell lymphoma refractory indolent b-cell relapsed indolent b-cell autologous stem-cell transplantation phosphoinositide-3-kinase-δ-γ post-germinal center biomarkers pi3k-delta inhibitor idelalisib b-cell lymphomas intensive front-line immunochemotherapy refractory aggressive b mantle cell lymphoma mantle-cell lymphoma kami maddocks md rituximab versus interferon-alfa mantle cell lymphomas full article pdf nordic lymphoma group received research funding bulky follicular lymphoma relapsed follicular lymphoma progression-free survival privacy choices/manage cookies lymphoma classification project molecular complete responses asymptomatic advanced-stage ohio state university phase ii study bcr signaling pathway gcb type lymphoma long-term effect diffuse large article maddocks phase ib study national lymphocare study r-cvp compared long-term follow high response rates

Questions {❓}

Early stage follicular lymphoma: is there a clinical impact of first-line treatment?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Ibrutinib in B-cell Lymphomas
         description:The standard frontline therapy for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) includes the use of chemoimmunotherapy and/or radiation therapy. When patients with these diseases relapse or are refractory to therapy, their diseases are considered incurable outside of the setting of an autologous or allogeneic stem cell transplant, which many patients are not candidates for due to age or comorbidities. The oral Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, targets the B-cell receptor (BCR) signaling pathway that is critical in the survival of these malignancies. It has shown promising activity in certain subtypes of DLBCL, in relapsed or refractory FL, and in relapsed or refractory MCL for which it has recently received FDA approval and should be considered for use in patients in first relapse. Ibrutinib is an oral therapy taken daily that has been well tolerated by patients. Given the high response rates, tolerability, and acceptable toxicities of ibrutinib therapy, it is now being evaluated in combination therapy both in relapsed B-cell malignancies and frontline studies in DLBCL and MCL. Several other promising agents targeting different kinases in the BCR signaling pathway also are currently under investigation.
         datePublished:2014-02-01T00:00:00Z
         dateModified:2014-02-01T00:00:00Z
         pageStart:226
         pageEnd:237
         sameAs:https://doi.org/10.1007/s11864-014-0274-8
         keywords:
            Diffuse large B cell lymphoma
            Follicular lymphoma
            Mantle cell lymphoma
            B-cell receptor signaling
            Bruton’s tyrosine kinase
            Ibrutinib
            Oncology
         image:
         isPartOf:
            name:Current Treatment Options in Oncology
            issn:
               1534-6277
               1527-2729
            volumeNumber:15
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Kami Maddocks
               affiliation:
                     name:The Ohio State University
                     address:
                        name:Department of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Kristie A. Blum
               affiliation:
                     name:The Ohio State University
                     address:
                        name:Department of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Ibrutinib in B-cell Lymphomas
      description:The standard frontline therapy for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) includes the use of chemoimmunotherapy and/or radiation therapy. When patients with these diseases relapse or are refractory to therapy, their diseases are considered incurable outside of the setting of an autologous or allogeneic stem cell transplant, which many patients are not candidates for due to age or comorbidities. The oral Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, targets the B-cell receptor (BCR) signaling pathway that is critical in the survival of these malignancies. It has shown promising activity in certain subtypes of DLBCL, in relapsed or refractory FL, and in relapsed or refractory MCL for which it has recently received FDA approval and should be considered for use in patients in first relapse. Ibrutinib is an oral therapy taken daily that has been well tolerated by patients. Given the high response rates, tolerability, and acceptable toxicities of ibrutinib therapy, it is now being evaluated in combination therapy both in relapsed B-cell malignancies and frontline studies in DLBCL and MCL. Several other promising agents targeting different kinases in the BCR signaling pathway also are currently under investigation.
      datePublished:2014-02-01T00:00:00Z
      dateModified:2014-02-01T00:00:00Z
      pageStart:226
      pageEnd:237
      sameAs:https://doi.org/10.1007/s11864-014-0274-8
      keywords:
         Diffuse large B cell lymphoma
         Follicular lymphoma
         Mantle cell lymphoma
         B-cell receptor signaling
         Bruton’s tyrosine kinase
         Ibrutinib
         Oncology
      image:
      isPartOf:
         name:Current Treatment Options in Oncology
         issn:
            1534-6277
            1527-2729
         volumeNumber:15
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Kami Maddocks
            affiliation:
                  name:The Ohio State University
                  address:
                     name:Department of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Kristie A. Blum
            affiliation:
                  name:The Ohio State University
                  address:
                     name:Department of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Treatment Options in Oncology
      issn:
         1534-6277
         1527-2729
      volumeNumber:15
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The Ohio State University
      address:
         name:Department of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, USA
         type:PostalAddress
      name:The Ohio State University
      address:
         name:Department of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Kami Maddocks
      affiliation:
            name:The Ohio State University
            address:
               name:Department of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Kristie A. Blum
      affiliation:
            name:The Ohio State University
            address:
               name:Department of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, USA
      name:Department of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(171)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

4.75s.